预约演示
更新于：2026-02-04
Selinexor
塞利尼索
更新于：2026-02-04
概要
基本信息
药物类型 小分子化药 |
别名 CRM1-nuclear-export-inhibitor、NEXPOVIO、Selinexor + [13] |
作用方式 抑制剂 |
作用机制 ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors)、XPO1抑制剂(输出蛋白1抑制剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-07-03), |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、加速批准 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (韩国)、孤儿药 (澳大利亚)、优先审评 (韩国)、优先审评 (美国)、附条件批准 (中国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H11F6N7O |
InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N |
CAS号1393477-72-9 |
关联
221
项与 塞利尼索 相关的临床试验NCT07369739
Golidocitinib Combined With Selinexor for the Treatment of Chronic Active Epstein-Barr Virus Disease (CAEBVD): A Multicenter, Prospective, Single-arm Clinical Study
NCT07200102
Selinexor Maintenance Post CAR-T Cell Therapy for Multiple Myeloma
NCT07276698
Clinical Study on Maintenance Therapy With Selinexor Combined With Azacitidine After Allogeneic Hematopoietic Stem Cell Transplantation for NK/T-cell Lymphoma
100 项与 塞利尼索 相关的临床结果
登录后查看更多信息
100 项与 塞利尼索 相关的转化医学
登录后查看更多信息
100 项与 塞利尼索 相关的专利（医药）
登录后查看更多信息
627
项与 塞利尼索 相关的文献（医药）2026-02-02CANCER RESEARCH
Disrupting Paraspeckle Stability by Targeting WTX–NONO Phase Separation Enhances Chemotherapy Efficacy in Gastric Cancer
Article
作者: Li, Yanyan ; Hung, Mien-Chie ; Du, Meihang ; An, Liwei ; Xu, Yangwei ; Li, Yi-Chuan ; Sun, Fei ; Qian, Xuexia ; Bai, Junping ; Zhang, Huanhu ; Lin, Zhihao ; Li, Xuanqi ; Zhang, Qingling ; Zhao, Zhangting ; Han, Lijun ; Ye, Zaisheng ; Chen, Zetao
Abstract:
Nuclear paraspeckles play critical roles in orchestrating gene transcription to support tumor development and progression. Elucidating regulators of their dynamic compositions and formation could provide potential targets for treating cancer. In this study, we discovered that the short isoform of Wilms tumor gene on the X chromosome (WTX-S) specifically disrupted paraspeckle stability. WTX-S selectively interacted with and sequestered NONO (also as p54nrb) from paraspeckles. Mechanistically, interaction between WTX-S and NONO induced formation of nuclear bodies via liquid–liquid phase separation (WTX-NB). The coiled-coil domain 2 directly interacted with NONO-coiled-coil domain to compartmentalize paraspeckle proteins and subsequently disrupt paraspeckle stability. Functionally, the paraspeckle disintegration induced by WTX-NBs resulted in enhanced chemotherapy sensitivity and favorable prognosis in gastric cancer. Importantly, the cell-penetrating synthetic peptide WTXAP, based on the WTX–NONO interface, mimicked WTX-NB–mediated paraspeckle disintegration and exhibited potent antitumor activity. Likewise, treatment with KPT-330, an FDA-approved XPO1 inhibitor, significantly increased the extent of WTX-S–mediated paraspeckle disintegration, sensitizing WTXhigh gastric cancer to chemotherapy. Collectively, these findings characterize the function and potential clinical significance of WTX-NBs, offering a strategy for sensitizing gastric cancer to chemotherapy.
Significance::
WTX binding to NONO regulates the balance of biomolecular condensates, providing an axis that can be harnessed to perturb paraspeckles and improve chemotherapy sensitivity in gastric cancer.
2026-02-01EJHaem
Successful Treatment of Refractory Sweet's Syndrome With Adalimumab in a Myelodysplastic Syndrome Patient
Article
作者: Zhu, Weifang ; Ma, Liya ; Suo, Shanshan ; Shen, Yaojia ; Wang, Lu ; Qiao, Jianjun ; Tong, Hongyan ; Chang, Jie
ABSTRACT:
We report a 69‐year‐old man diagnosed as myelodysplastic syndrome and administrated with azacitidine and selinexor treatment. Then he was revealed high fever and multiple tender erythematous papules involving his mouth, back, upper and lower extremities, which were diagnosed as Sweet's syndrome by skin biopsy. He was administrated with adalimumab and his rashes gradually disappeared after adalimumab treatment. But he had secondary disseminated fungal infections. Finally, he died of heart failure and severe infection.Trial Registration: The authors have confirmed clinical trial registration is not needed for this submission
2026-01-01BIOORGANIC CHEMISTRY
Therapeutic horizons in targeting XPO1 with small inhibitor molecules: Recent achievements, synthetic strategies, opportunities, challenges, and future perspectives
Review
作者: Abulkhair, Hamada S
XPO1 governs the cytoplasmic translocation of tumor suppressors, growth regulators, and viral components from the nucleus to the cytoplasm, playing a pivotal role in cancer progression and viral replication. XPO1 inhibition has also been shown to modulate immune responses, particularly by altering NF-κB signaling and cytokine export. In oncology, these inhibitors restore nuclear tumor suppressor function and induce apoptosis. In virology, they block the export of essential viral proteins and RNA, impairing viral replication. Over the last five years, substantial advancements have been made in developing small-molecule XPO1 inhibitors. The FDA approval of Selinexor marked a major milestone followed by second-generation compounds such as Eltanexor and Verdinexor. A diverse array of heterocycles including azoles, azines, fluorinated aromatics, α,β-unsaturated carbonyls, sulfonamides, isothiocyanates, chromenes, indoles, and bacterial metabolites has been subsequently developed to optimize drug-like properties and biological activity. This review highlights the therapeutic applications, biological roles, the mechanisms of inhibition, recent preclinical and clinical achievements, and emerging opportunities in anticancer and antiviral therapeutics mediated by XPO1 inhibition. Specifically, this review emphasizes the detailed adopted chemical strategies for the development of XPO1 small molecule inhibitors and their emerging inhibition mechanisms, aiming to support future XPO1 inhibitor design.
621
项与 塞利尼索 相关的新闻（医药）2026-01-30
2026-01-26
临床研究抗体药物偶联物诊断试剂
2026-01-25
100 项与 塞利尼索 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 滤泡性淋巴瘤 | 印尼 | 2025-03-05 | |
| 难治性多发性骨髓瘤 | 中国 | 2021-12-14 | |
| 复发性多发性骨髓瘤 | 中国 | 2021-12-14 | |
| 复发性弥漫性大B细胞淋巴瘤 | 以色列 | 2021-02-04 | |
| 难治性弥漫性大 B 细胞淋巴瘤 | 以色列 | 2021-02-04 | |
| 弥漫性大B细胞淋巴瘤 | 美国 | 2020-06-22 | |
| 多发性骨髓瘤 | 美国 | 2019-07-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 难治性急性髓细胞白血病 | 临床3期 | 中国 | 2023-01-29 | |
| 复发性急性髓细胞白血病 | 临床3期 | 中国 | 2023-01-29 | |
| 子宫内膜癌 | 临床3期 | 中国 | 2021-10-27 | |
| 子宫内膜癌 | 临床3期 | 中国 | 2021-10-27 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 美国 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 澳大利亚 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 比利时 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 保加利亚 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 加拿大 | 2021-03-11 | |
| 真性红细胞增多症后骨髓纤维化 | 临床3期 | 捷克 | 2021-03-11 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 4 | 憲顧網襯鹹選鏇網鬱願 = 蓋簾窪觸顧範壓顧鹹鹹 廠顧餘遞廠鬱選鏇淵壓 (夢膚夢積網憲積餘願網, 窪糧構鬱憲願醖築獵衊 ~ 醖窪膚鹹願築艱築鏇鑰) 更多 | - | 2026-01-29 | |||
临床2期 | 11 | Selinexor plus R-CHOP | 衊夢夢壓窪糧鑰簾顧襯(選鹽顧獵製積衊醖夢鏇) = 齋繭積艱網憲選願觸蓋 製鑰艱遞築憲襯鬱獵製 (窪糧夢範膚鏇顧糧壓範 ) 更多 | 积极 | 2025-12-06 | ||
临床3期 | 多发性骨髓瘤 维持 | 149 | 選衊鑰鹽夢構選壓衊構(鬱遞鏇簾範願積蓋夢糧) = 艱願廠夢鏇淵蓋顧積選 醖襯鏇構構顧鑰壓遞襯 (觸構簾顧鬱願鏇網餘鑰 ) 更多 | 不佳 | 2025-12-06 | ||
選衊鑰鹽夢構選壓衊構(鬱遞鏇簾範願積蓋夢糧) = 糧簾艱餘遞鬱蓋鹹餘網 醖襯鏇構構顧鑰壓遞襯 (觸構簾顧鬱願鏇網餘鑰 ) 更多 | |||||||
临床2期 | 肾功能不全 一线 | 63 | 遞壓壓鏇壓廠窪蓋壓鏇(衊鑰願憲範齋醖廠憲鏇) = 製範選簾獵鬱積簾簾鑰 築鑰獵範製獵蓋積窪廠 (壓憲淵餘餘艱鏇範簾簾 ) 更多 | 积极 | 2025-12-06 | ||
临床1/2期 | 多发性骨髓瘤 一线 | 21 | 鏇膚製願鬱壓廠繭選醖(廠繭憲憲遞蓋簾選築膚) = 觸衊構壓糧鬱獵齋醖襯 構糧糧網憲憲願鬱齋鬱 (窪鬱艱蓋艱憲壓製簾壓 ) 更多 | 积极 | 2025-12-06 | ||
临床2期 | 44 | Selinexor + R-CHOP | 遞齋廠夢觸範觸鹽觸壓(顧齋餘窪廠艱鑰淵遞憲) = 淵選襯壓範襯製觸鹹築 觸獵鏇襯襯簾鬱醖壓醖 (願簾繭夢範鹽製廠醖醖 ) 更多 | 积极 | 2025-12-06 | ||
临床1期 | 20 | Selinexor in combination with azacitidine or Ruxolitinib | 夢築鹽築壓鏇餘齋餘齋(夢鬱繭艱網夢襯襯積築) = 鹹鹽築鹹觸遞齋顧衊憲 鹽糧壓餘衊鏇壓顧網襯 (構鹹選製夢淵蓋繭膚壓 ) | 积极 | 2025-12-06 | ||
Selinexor in combination with azacitidine or Ruxolitinib | 夢築鹽築壓鏇餘齋餘齋(夢鬱繭艱網夢襯襯積築) = 艱選鏇遞簾範壓簾糧簾 鹽糧壓餘衊鏇壓顧網襯 (構鹹選製夢淵蓋繭膚壓 ) | ||||||
N/A | 54 | 齋築艱淵積餘齋壓製積(鏇醖選鹽製憲壓廠獵獵) = Grade 1 occurred in 9 patients (60%) and 28 patients (71.8%), respectively; Grade 2 in 1 patient (6.7%) and 4 patients (10.3%); Only one patient in the selinexor-based regimen group experienced Grade 4 (6.7%) CRS. There is no difference between the selinexor-based group and alternative regimen groups (grade 1-4: 73.3% vs 82.1% p=0.475; grade 3 and 4: 6.7% vs 0%; p=0.278). 窪夢觸衊醖鹽齋製簾襯 (膚製鑰艱顧醖襯窪衊窪 ) 更多 | 积极 | 2025-12-06 | |||
Alternative regimen bridging CAR-T cell therapy | |||||||
N/A | 32 | 壓糧觸觸齋廠襯醖蓋餘(餘選構獵鹹夢顧襯襯鬱) = Except for the initial case exhibiting severe vomiting, no grade 4-5 hematological adverse events(CTCAE v5.0) or transplant-related deaths were observed. 餘構齋選簾糧願鹽壓餘 (鑰膚鏇衊鹹觸蓋襯築鹹 ) | 积极 | 2025-12-06 | |||
临床1/2期 | 骨髓增生异常综合征 TP53 | 39 | (TP53 mutations) | 繭窪鹽願鏇衊衊窪網鹹(醖顧艱築醖網網鹽醖選) = 窪願窪膚顧壓鏇繭製鹹 製醖繭淵淵觸衊範選積 (選鹹網鏇膚壓齋艱鹽鹹 ) 更多 | 积极 | 2025-12-06 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用